

## UNITED STATES PARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

SERIAL NUMBER UB/591,447	FILING DATE U4/18/9	FIRST NAMED APPLIC 6 QUENTIN-MILLET	ANT M	ATTORNEY DOCKET NO. X1/F02956US0
Γ		1		
marina and an ender		18N2/1107		EXAMINER
THOMAS P SARRO LARSON & TAYLOR		PAK,M		
727 23RD S	TREET SOUT	H	ART UNIT	PAPER NUMBER
ARLINGTON VA 22202		1812		
l		J	DATE MAILED:	11/07/96

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

Serial No. 08/591,447 Art Unit 1812

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and / or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And / Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN 30 DAYS FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Michael D. Pak, whose telephone number is (703) 305-7038. The Examiner can normally be reached Mondays through Fridays from 8:30 a.m. to 5:00 p.m. The fax number for the Group is (703) 305-0294.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Stephen Walsh, can be reached at (703) 308-2957.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group Receptionist, whose telephone number is (703) 308-0196.

MAP

Michael Pak 1812

> DAVID L. FITZGERALD PRIMARY EXAMINER GROUP 1800

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this appliant comply with the requirements for such a disclosure as set forth in 37 Cl 1.825 for the following reason(s):	ication does FR 1.821 -
1. This application clearly fails to comply with the requirements of	37 CFR 1.821
- 1.825. Applicant's attention is directed to these regulations, published May 15, 1990 and at 55 FR 18230, May 1, 1990.	at 1114 OG 29,
2. This application does not contain, as a separate part of the disc	losure on
paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).	
3. A copy of the "Sequence Listing" in computer readable form has no	t been
submitted as required by 37 CFR 1.821(e).	-,
	<u>;</u>
A A copy of the "Sequence Listing" in computer modelle form the bar	
4. A copy of the "Sequence Listing" in computer readable form has be	
However, the content of the computer readable form does not comply with the of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marks Sequence Listing."	requirements ed-up "Raw
5. The computer readable form that has been filed with this applicat	ion has been
found to be damaged and/or unreadable as indicated on the attached CRF Disks Report. A substitute computer readable form must be submitted as required 1.825(d).	ette Problem by 37 CFR
6. The paper copy of the "Sequence Listing" is not the same as the co	omputer
readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).	· ·
7.	
Other:	
Applicant must provide:	v
An initial or substitute computer readable form (CRF) copy of the "Sec	quence
Listing"	
An initial or substitute paper copy of the "Sequence Listing", as well	l as an
amendment directing its entry into the specification	
A statement that the content of the paper and computer readable copies	s are the same
and, where applicable, include no new matter, as required by 37 CFR 1 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)	
For questions regarding compliance with these requirements, ple	ase contact:
For Rules Interpretation, call (703) 308-1123	
For CRF submission help, call (703) 308-4212	
For PatentIn coftware boln call (702) 557 0400	

Please return a copy of this notice with your response.